Skip to main content
Journal cover image

Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program

Publication ,  Conference
Shen, Q; Xu-Monette, ZY; Manyam, GC; Visco, C; Tzankov, A; Cao, X; Deng, L; Montes-Moreno, S; Dybkær, K; Chiu, A; Orazi, A; Zu, Y; Bhagat, G ...
Published in: Clinical Lymphoma Myeloma and Leukemia
June 2015

Duke Scholars

Published In

Clinical Lymphoma Myeloma and Leukemia

DOI

ISSN

2152-2650

Publication Date

June 2015

Volume

15

Start / End Page

S220 / S221

Publisher

Elsevier BV

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Shen, Q., Xu-Monette, Z. Y., Manyam, G. C., Visco, C., Tzankov, A., Cao, X., … Young, K. H. (2015). Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program. In Clinical Lymphoma Myeloma and Leukemia (Vol. 15, pp. S220–S221). Elsevier BV. https://doi.org/10.1016/j.clml.2015.04.096
Shen, Qi, Zijun Y. Xu-Monette, Ganiraju C. Manyam, Carlo Visco, Alexander Tzankov, Xin Cao, Lijuan Deng, et al. “Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program.” In Clinical Lymphoma Myeloma and Leukemia, 15:S220–21. Elsevier BV, 2015. https://doi.org/10.1016/j.clml.2015.04.096.
Shen Q, Xu-Monette ZY, Manyam GC, Visco C, Tzankov A, Cao X, et al. Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program. In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2015. p. S220–1.
Shen, Qi, et al. “Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program.” Clinical Lymphoma Myeloma and Leukemia, vol. 15, Elsevier BV, 2015, pp. S220–21. Crossref, doi:10.1016/j.clml.2015.04.096.
Shen Q, Xu-Monette ZY, Manyam GC, Visco C, Tzankov A, Cao X, Deng L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, Han van Krieken J, Huh J, Ponzoni M, Ferreri AJM, Farnen JP, Møller MB, Winter JN, Piris MA, Medeiros LJ, Young KH. Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program. Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2015. p. S220–S221.
Journal cover image

Published In

Clinical Lymphoma Myeloma and Leukemia

DOI

ISSN

2152-2650

Publication Date

June 2015

Volume

15

Start / End Page

S220 / S221

Publisher

Elsevier BV

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences